Casdin Capital, LLC Bluebird Bio, Inc. Transaction History

Casdin Capital, LLC

  • $1.29 Billion
  • Q3 2024

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2021

May 17, 2021
SELL
$16.59 - $33.89 $15.2 Million - $31 Million
-915,000 Closed
0 $0
Q3 2020

Nov 16, 2020
SELL
$34.44 - $43.75 $6.54 Million - $8.31 Million
-190,000 Reduced 17.19%
915,000 $49.4 Million
Q1 2020

May 15, 2020
BUY
$26.16 - $63.5 $3.53 Million - $8.57 Million
135,000 Added 13.92%
1,105,000 $50.8 Million
Q4 2019

Feb 14, 2020
BUY
$46.96 - $61.67 $16.8 Million - $22 Million
357,500 Added 58.37%
970,000 $85.1 Million
Q3 2019

Nov 12, 2019
BUY
$59.47 - $93.1 $14.3 Million - $22.3 Million
240,000 Added 64.43%
612,500 $56.2 Billion
Q2 2019

Aug 13, 2019
BUY
$75.84 - $105.21 $1.14 Million - $1.58 Million
15,000 Added 4.2%
372,500 $0
Q1 2019

May 15, 2019
BUY
$64.44 - $104.11 $1.77 Million - $2.86 Million
27,500 Added 8.33%
357,500 $56.2 Million
Q4 2018

Feb 13, 2019
BUY
$59.1 - $93.26 $4.26 Million - $6.71 Million
72,000 Added 27.91%
330,000 $32.7 Million
Q3 2018

Nov 14, 2018
BUY
$88.86 - $117.49 $5.15 Million - $6.81 Million
58,000 Added 29.0%
258,000 $37.7 Million
Q2 2018

Aug 14, 2018
BUY
$99.64 - $127.59 $5.48 Million - $7.02 Million
55,000 Added 37.93%
200,000 $31.4 Million
Q3 2017

Nov 14, 2017
BUY
$57.74 - $91.42 $8.37 Million - $13.3 Million
145,000
145,000 $19.9 Million

Others Institutions Holding BLUE

# of Institutions
152
Shares Held
63.7M
Call Options Held
264K
Put Options Held
428K
View Full List

About bluebird bio, Inc.

BLUE Quotes by TradingView
  • Ticker BLUE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,121,800
  • Market Cap $25.5M
  • Description
  • bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...
More about BLUE
Track This Portfolio

Track Casdin Capital, LLC Portfolio

Follow Casdin Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Casdin Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Casdin Capital, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email